Download PDF version

Medicinal Chemistry 

IRBM SP comprises the core medicinal chemistry team behind the discovery of the first-in- class HIV-I ntegrase inhibitor Isentress TM. Strong organic synthesis exper ience underpins our medicinal chemistry efforts that take a highly focused and multidisciplinary approach toward the evolution of leads to developable drug candidates. We provide services in many areas of medicinal chemistry : early lead identification, hit-to -lead evolution, lead optimization, and identification of preclinical candidates.

Peptide Chemistry

IRBM SP is a world- class centre for the discovery and development of peptide therapeutics. Our peptide candidates are designed by approaches such as biocomputing, structural biology and the development of structure-activity relationships through the focused synthesis of multiple peptide analogs. Our experience covers a wide range of technologies, including the use of non- coded amino acids, conformational constraints, modification of the peptide back bone, and conjugation with PK- enhancing moieties.

Distinguiishing Features

• Industry experience
  • Former Merck small molecule drug discovery group
  • Former Merck ‘Centre of Excellence for Peptide Therapeutics’

• Track record of drug and vaccine discovery
  • First-in- class HIV integrase inhibitor IsentressTM on the market
  • > 10 agents in preclinical and clinical development
  • Peptide mimetic vaccines

• Strong synthetic chemistry know-how
  • Experience in a broad range of chemical classes
  • Core expertise in peptide and peptidomimetic chemistry
  • PK- enhancing approaches and peptide conjugates
  • Complex multistep synthesis: design and implementation
  • Technology enabled synthesis for rapid analog generation
  • Large scale synthesis up to 1 kg (non GLP)

• High-throughput automated purification expertise

• Ability to operate from hit to preclinical candidate
  • Experience in a broad range of chemical classes

• Experience in the coordination of development through to phase Ib
  • Comprehensive small molecule and peptide drug discovery programs aimed at the generation of preclinical development candidate or peptide
    mimetic vaccines
  • Custom synthesis of individual compounds up to 1 kg (non-GLP)
  • Custom peptide synthesis including constrained, labeled and conjugated structures
  • Custom synthesis of libraries of small molecules or peptides
  • High throughput purification of compound arrays
  • Consulting services for drug discovery efforts from hit identification to Phase 1b
  • Consulting support for large-scale peptide manufacturing
  • IP support